DOCSLIB.ORG

Intraoperative Vasoplegia: Methylene Blue to the Rescue!

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Intraoperative Vasoplegia: Methylene Blue to the Rescue! CE: Tripti; ACO/310110; Total nos of Pages: 7; ACO 310110 REVIEW CURRENT OPINION Intraoperative vasoplegia: methylene blue to the rescue! Sharon L. McCartneya, Lorent Duceb, and Kamrouz Ghadimia Purpose of review To evaluate the efficacy, dosing, and safety of methylene blue (MTB) in perioperative vasoplegic syndrome (VS). Recent findings Vasoplegic syndrome is a state of persistent hypotension with elevated cardiac output, low filling pressures, and low systemic vascular resistance (SVR). It occurs in up to 25% of patients undergoing cardiac surgery with cardiopulmonary bypass, can last up to 72 h, and is associated with a high mortality rate. MTB has been found to increase SVR and decrease vasopressor requirements in vasoplegic syndrome by inhibiting nitric oxide synthase, thus limiting the generation of nitric oxide, while inhibiting activation of soluble guanylyl cyclase and preventing vasodilation. MTB has been used in postgraft reperfusion during liver transplantation and anaphylaxis in a limited number of cases. Additionally, this medication has been used in septic shock with promising results, but similar to the cardiac surgical population, the effects of MTB administration on clinical outcomes has yet to be elucidated. Summary MTB should be considered during vasoplegic syndrome in cardiac surgery with cardiopulmonary bypass and usage may be more effective in an early critical window, prior to end-organ hypoperfusion. Other perioperative scenarios of MTB use show promise, but additional studies are required to develop formative conclusions. Keywords cardiac surgery, cardiopulmonary bypass, methylene blue, nitric oxide, vasoplegia INTRODUCTION beta blockers, calcium channel blockers, amiodar- Vasoplegic syndrome involves severe hypotension one, and use of protamine [3]. Other risk factors with normal or elevated cardiac output, tachycardia include low preoperative ejection fraction, higher in patients who may reliably mount a compensatory additive European System for Cardiac Operative Risk response to hypotension, reduced cardiac filling Evaluation (EuroSCORE) value [6], increased dura- tion of cardiopulmonary bypass (CPB), and blood pressures, and decreased systemic vascular resis- & tance (SVR) [1]. Intravascular volume expansion product administration [3,5 ]. does not typically improve the hemodynamic pro- Two distinct mechanisms are responsible for the file and aside from such clinical presentation, the loss of vascular tone and include: (1) activation of exact definition of vasoplegic syndrome remains nitric oxide synthase (NOS) with dysregulation of poorly defined. Proposed definitions encompass hypotension with mean arterial pressures (MAP) less than 50 mmHg, which is secondary to low SVR and aDivisions of Cardiothoracic Anesthesia and Critical Care Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, normal or supranormal cardiac output. This b prompts increased requirements for fluids and North Carolina, USA and Division of Cardiothoracic Anesthesia, Depart- ment of Anesthesiology, University of Florida, Gainesville, Florida, USA high-dose vasopressor therapy [2,3] but ultimately Correspondence to Kamrouz Ghadimi, MD, Divisions of Cardiothoracic a state of vasodilatory shock remains with lack of Anesthesia and Critical Care Medicine, Department of Anesthesiology, adequate perfusion pressure because of extremely Duke University Medical Center, Box 3094/HAFS 5691G, Durham, NC & low vascular tone [4,5 ]. 27710, USA. Tel: +1 919 681 6532; Several risk factors for vasoplegic syndrome have e-mail: [email protected] been identified, including preoperative intravenous Curr Opin Anesthesiol 2017, 30:000–000 heparin, angiotensin-converting enzyme inhibitors, DOI:10.1097/ACO.0000000000000548 0952-7907 Copyright ß 2017 Wolters Kluwer Health, Inc. All rights reserved. www.co-anesthesiology.com Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. CE: Tripti; ACO/310110; Total nos of Pages: 7; ACO 310110 Cardiovascular anesthesia patients undergoing cardiac surgery and quickly KEY POINTS extending use to other surgical populations [8]. Methylene blue causes vasoconstriction by inhibiting inducible nitric oxide synthase and preventing subsequent activation of soluble guanylyl cyclase, in MECHANISM OF ACTION addition to directly inhibiting soluble guanylyl cyclase MTB is an odorless, water soluble, dark blue-green in smooth muscle cells. crystalline powder, which turns blue whenever Most prospective and observational studies show that mixed in solution [9] and is often used as a dye in methylene blue causes an increase in systemic blood several medical procedures. As a vasopressor, MTB pressure and decrease in vasopressor requirements impacts the NO synthetic pathway by inhibiting during vasoplegic syndrome after cardiac surgery, but inducible NOS and inhibiting the subsequent acti- improvement in morbidity and mortality have not been vation of sGC (Fig. 1) [10]. In addition, by binding to consistently demonstrated. the iron heme moiety of sGC and causing enzyme Expansion of methylene blue into other perioperative inhibition, MTB blocks accumulation of cyclic GMP uses, such as reperfusion after orthotopic liver (cGMP), competing directly with NO in its ability to transplantation and shock related to anaphylaxis or activate soluble guanylyl cyclase (Fig. 1) [10]. sepsis, show promise, but further investigation is warranted. INTRAOPERATIVE USE OF METHYLENE BLUE MTB may be used for hypotension refractory to nitric oxide (NO) synthesis and activation of vascular high-dose vasopressors and intravascular volume smooth muscle cell-soluble guanylyl cyclase (sGC) administration during the perioperative setting activation (Fig. 1) [3]. The same Brazilian group that and has been used extensively in the cardiac surgical first reported perioperative vasoplegic syndrome, uti- population. It has also been used in liver transplan- lized methylene blue (MTB) as an inhibitor of NO tation for hypotension following graft reperfusion, synthesis and described their success in six patients anaphylaxis, carcinoid syndrome, and burn injuries. [7]. In this letter to the editor, MTB was able to restore In a meta-analysis of five randomized controlled vascular tone, normalize MAP, and reduce vasopres- trials (n ¼ 174), MTB was found to modestly increase sor usage [7]. Subsequently, a few supportive random- arterial blood pressure [weighted mean difference, ized trials and retrospective observational studies 6.93 mmHg; 95% confidence interval (CI) 1.67– were published, and MTB became recognized as a 12.18; P ¼ 0.01] without an adverse effect on mor- viable option for treating vasoplegic syndrome in tality [6% (14/88)] among MTB-treated patients and FIGURE 1. Mechanism of action of methylene blue. Methylene blue inhibits nitric oxide synthase and soluble guanylyl cyclase, preventing cGMP accumulation and vasodilation within smooth muscle. cGMP, cyclic guanosine monophosphate; GTP, guanosine 5’-triphosphate; MTB, methylene blue; NO, nitric oxide; NOS, nitric oxide synthase; sGC, soluble guanylyl cyclase. 2 www.co-anesthesiology.com Volume 30 Number 00 Month 2017 Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. CE: Tripti; ACO/310110; Total nos of Pages: 7; ACO 310110 Intraoperative vasoplegia McCartney et al. 23% (20/86) in the control group (OR 0.65; 95% Ozal et al. [20] administered MTB at 1 h prior to CI, 0.21–2.08; P ¼ 0.5) [11]. cardiac surgery in patients with risk factors for vaso- plegic syndrome, and found higher SVR (P < 0.001), less norepinephrine usage between groups (2/50 Cardiac surgery versus 41/50, P < 0.001), and reduced intravascular Vasoplegic syndrome after cardiac surgery on CPB is volume administration in patients who received thought to be largely the result of a severe inflamma- MTB (1577 versus 1749 ml, P ¼ 0.024). tory response [1,3]. During CPB, plasma proteins are Timing of MTB administration seems to effect absorbed by biomembranes, resulting in contact sys- the hemodynamic response in cardiac surgical tem activation of the extrinsic and intrinsic coagula- patients. In a retrospective study of 88 vasoplegic tion pathways, complement system activation, and patients, MTB administration resulted in higher fibrinolysis [3,12]. Activation of these pathways cre- MAP when compared with patients that did not ates secretion of cytokines that activate endothelial receive MTB (OR 1.04, 95% CI 1.01–1.07, cells and release vasoactive substances, including P ¼ 0.02). In particular, patients that underwent NO and prostacyclin [13]. Additional aspects that deep hypothermic circulatory arrest for complex may contribute to the profound inflammatory aortic repair experienced a greater hemodynamic response during cardiac surgery include reinfusion improvement after receiving MTB (23.9%, n ¼ 21; of hemolyzed cardiotomy blood that consists of other OR 4.48, 95% CI 1.54–13.06; P ¼ 0.006). [21&&]. activated substrates, and removal of the aortic cross- These findings suggest that the use of MTB as a last clamp, which may cause an ischemia-reperfusion resort agent may not be an appropriate strategy for syndrome through neutrophil activation and release the treatment of vasoplegic syndrome and earlier of reactive oxygen species [3,13]. Vasoplegic syn- use is recommended in at-risk patients. drome may occur in 5–25% of patients undergoing Controversially, MTB has been suggested for the cardiac surgery using CPB,
Load more

Recommended publications
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Isocarboxazid Item No. 23625 CAS Registry No.: 59-63-2 Formal Name: 5-methyl-3-isoxazolecarboxylic acid, 2-(phenylmethyl)hydrazide Synonyms: NSC 169893, Ro 5-0831 H N N H MF: C12H13N3O2 FW: 231.3 N O Purity: ≥98% O Supplied as: A solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Isocarboxazid is supplied as a solid. A stock solution may be made by dissolving the isocarboxazid in the solvent of choice. Isocarboxazid is slightly soluble in acetonitrile and chloroform. Description 1 Isocarboxazid is an inhibitor of monoamine oxidase (MAO; IC50 = 4.8 μM for rat brain MAO). It induces a 4-fold increase in tryptamine action in isolated rat fundal strips at a concentration of 50 nM. In vivo, isocarboxazid potentiates tryptamine toxicity (LD50 = 8 mg/kg following subcutaneous administration of 250 mg/kg tryptamine). It inhibits 90% of MAO activity in isolated rat hearts and reduces cardiomegaly induced by isoproterenol (Item No. 15592) in rats at a dose of 20 mg/kg.2 Oral administration of isocarboxazid (10 mg/kg) increases levels of dopamine and norepinephrine and reduces levels of the monoamine metabolites DOPAC, homovanillic acid (HVA; Item No. 20877), and 5-hydroxy indole-3-acetic acid (5-HIAA; Item No. 22889) by 43, 32, and 28%, respectively, in mouse brain.3 Formulations containing isocarboxazid have been used for the treatment of minor depression.4 References 1. Maxwell, D.R., Gray, W.R., and Taylor, E.M. Relative activity of some inhibitors of mono-amine oxidase in potentiating the action of tryptamine in vitro and in vivo.
    [Show full text]
  • Studies on the Metabolism and Toxicity of Hydrazine in The~Rat~
    STUDIES ON THE METABOLISM AND TOXICITY OF HYDRAZINE IN THE~RAT~ Andrew Michael Jenner, B.Sc. Submitted to the University of London for the examination of the degree for Doctor of Philosophy, 1992 Toxicology Department The School of Pharmacy Brunswick Square London ProQuest Number: U068521 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest U068521 Published by ProQuest LLC(2017). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 ACKNOWLEDGEMENTS I would like to express my sincere appreciation to my supervisor Dr. John Timbrell for his invaluable advice, guidance and support. Many people have assisted the progress of my studies in a wide variety of ways, including everyone who has worked alongside me in the Toxicology Unit, both past and present. Particular thanks go to Simon (ET) for his critical eye and mutual, down to earth Yorkshire mentality and also to Cathy for her heartening encouragement. I would also like to thank Dr. Alan Boobis for his assistance in obtaining human liver samples and to the USAF for funding this project. Finally I would like to recognise Jacqui for her designs, Maria for her typing, Justina for her continuous care and support and to my mum and dad for their understanding and my much appreciated conveyance through life.
    [Show full text]
  • Ayahuasca: Spiritual Pharmacology & Drug Interactions
    Ayahuasca: Spiritual Pharmacology & Drug Interactions BENJAMIN MALCOLM, PHARMD, MPH [email protected] MARCH 28 TH 2017 AWARE PROJECT Can Science be Spiritual? “Science is not only compatible with spirituality; it is a profound source of spirituality. When we recognize our place in an immensity of light years and in the passage of ages, when we grasp the intricacy, beauty and subtlety of life, then that soaring feeling, that sense of elation and humility combined, is surely spiritual. The notion that science and spirituality are somehow mutually exclusive does a disservice to both.” – Carl Sagan Disclosures & Disclaimers No conflicts of interest to disclose – I don’t get paid by pharma and have no potential to profit directly from ayahuasca This presentation is for information purposes only, none of the information presented should be used in replacement of medical advice or be considered medical advice This presentation is not an endorsement of illicit activity Presentation Outline & Objectives Describe what is known regarding ayahuasca’s pharmacology Outline adverse food and drug combinations with ayahuasca as well as strategies for risk management Provide an overview of spiritual pharmacology and current clinical data supporting potential of ayahuasca for treatment of mental illness Pharmacology Terms Drug ◦ Term used synonymously with substance or medicine in this presentation and in pharmacology ◦ No offense intended if I call your medicine or madre a drug! Bioavailability ◦ The amount of a drug that enters the body and is able to have an active effect ◦ Route specific: bioavailability is different between oral, intranasal, inhalation (smoked), and injected routes of administration (IV, IM, SC) Half-life (T ½) ◦ The amount of time it takes the body to metabolize/eliminate 50% of a drug ◦ E.g.
    [Show full text]
  • The Effects of Phenelzine and Other Monoamine Oxidase Inhibitor
    British Journal of Phammcology (1995) 114. 837-845 B 1995 Stockton Press All rights reserved 0007-1188/95 $9.00 The effects of phenelzine and other monoamine oxidase inhibitor antidepressants on brain and liver 12 imidazoline-preferring receptors Regina Alemany, Gabriel Olmos & 'Jesu's A. Garcia-Sevilla Laboratory of Neuropharmacology, Department of Fundamental Biology and Health Sciences, University of the Balearic Islands, E-07071 Palma de Mallorca, Spain 1 The binding of [3H]-idazoxan in the presence of 106 M (-)-adrenaline was used to quantitate 12 imidazoline-preferring receptors in the rat brain and liver after chronic treatment with various irre- versible and reversible monoamine oxidase (MAO) inhibitors. 2 Chronic treatment (7-14 days) with the irreversible MAO inhibitors, phenelzine (1-20 mg kg-', i.p.), isocarboxazid (10 mg kg-', i.p.), clorgyline (3 mg kg-', i.p.) and tranylcypromine (10mg kg-', i.p.) markedly decreased (21-71%) the density of 12 imidazoline-preferring receptors in the rat brain and liver. In contrast, chronic treatment (7 days) with the reversible MAO-A inhibitors, moclobemide (1 and 10 mg kg-', i.p.) or chlordimeform (10 mg kg-', i.p.) or with the reversible MAO-B inhibitor Ro 16-6491 (1 and 10 mg kg-', i.p.) did not alter the density of 12 imidazoline-preferring receptors in the rat brain and liver; except for the higher dose of Ro 16-6491 which only decreased the density of these putative receptors in the liver (38%). 3 In vitro, phenelzine, clorgyline, 3-phenylpropargylamine, tranylcypromine and chlordimeform dis- placed the binding of [3H]-idazoxan to brain and liver I2 imidazoline-preferring receptors from two distinct binding sites.
    [Show full text]
  • University of Colorado Denver Anschutz Medical Campus Msa Capstone Presenations
    UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS ANNUAL STUDENT MSA CAPSTONE PRESENTATIONS MARCH 2, 2017 ANSCHUTZ MEDICAL CAMPUS HEALTH AND SCIENCES LIBRARY UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS MSA CAPSTONE PRESENATIONS Thursday, March 2, 2017 Poster Sessions Session A: 1:00 pm – 2:00 pm Session B: 2:15 pm – 3:15 pm Session C: 3:30 pm – 4:30 pm ANSCHUTZ MEDICAL CAMPUS Health Sciences Library The MSA Directors to acknowledge, with gratitude, the support for medical student research provided by: The University of Colorado Denver School of Medicine Dean’s Office And Undergraduate Medical Education Office Poster Session Judges The organizing committee wishes to acknowledge their appreciation to the following serving as judges for the MSA Capstone Presentations. Without their generous contribution of time and talent the forum would not be possible. Thank you! Madiha Abdel-Maksoud, MP, MSPH, PhD Rooban Nahomi, PhD David Ammar, PhD Matthew Nalty, BA Ilango Balakrishnan, PhD Kristen Nowak, PhD, MPH Carl Barnes, MD David Orlicky, Ph.D. Adria Boucharel, MD David Orlicky, Ph.D. Joseph Brzezinski, PhD Clare Paterson, PhD William Cornwell. MD Karin Payne, PhD Colleen Dingmann, R.N, Ph.D. Mark Petrash, PhD Michele Doucette, Ph.D. Miriam Post, MD Charles Edelstein, MD, PhD Allan Prochazka, MD, MSc Adit Ginde, MD, MPH Laura Pyle, PhD Jackie Glover, Ph.D Cordelia Robinson Rosenberg, PhD, RN Daniel Goldberg, JD, PhD Joseph Sakai, MD Maryam Guiahi, MD, MSc David Schwartz, MD Pearce Korb, MD Robert Sclafani, PhD Luidmila Kulik, PhD Deb Seymour, PsyD Rita Lee, MD Nicole Tartaglia, MS, MD Steven Lowenstein, MD, MPH Jean Tsai, MD, PhD Wendy Macklin, PhD Catherine Velopulos, MD, MHS Sandy Martin, PhD Laura Wiley, PhD Leana May DO, MPH Seonghwan Yee, PhD Jose Mayordomo, Ph.D.
    [Show full text]
  • Ready, Set, (Vaso)Action! Vasoactive Agents for Catecholamine Refractory
    Lights, Camera, (Vaso)Action! Vasoactive Agents for Catecholamine Refractory Septic Shock Gregory Kelly, Pharm.D. PGY2 Emergency Medicine Pharmacy Resident University of Rochester Medical Center October 28, 2017 Conflicts of Interest I have no conflicts of interest to disclose Presentation Objectives 1. Discuss the currently available literature evaluating angiotensin II as a treatment modality for septic shock. 2. Interpret the results of the ATHOS-3 trial and its applicability to the management of patients with septic shock. Vasopressin Vasopressin: A History Case series of vasopressin First case report deficiency in in severe shock septic shock 1960-80’s 1954 1957 1997 2003 Vasopressin Use of First RCT first vasopressin for suggesting synthesized GI superiority of hemorrhage, vasopressin + diabetes norepinephrine to insipidus and norepinephrine ileus alone Matis-Gradwohl I, et al. Crit Care. 2013;17:1002. VAAST Trial: design VASST Trial Design Mutlicenter, international, randomized, double-blind trial • n = 778 Population • Refractory septic shock Intervention Vasopressin 0.01-0.03 units/min vs. Norepinephrine alone Russell JA, et al. New Engl J Med. 2008;358:877-87. Drug Titration Vasopressin start at 0.01 units/min Titrate by 0.005 units/min Every 10 minutes to reach max of 0.03 units/min MAP ≥65-70mmHg MAP <65-70mmHg Decrease Increase norepinephrine by norepinephrine 1-2 mcg/min every 5-10 minutes Russell JA, et al. New Engl J Med. 2008;358:877-87. Norepinephrine Requirements Norepinephrine Vasopressin Russell JA, et al. New Engl J Med. 2008;358:877-87. Mortality 450 Day 28 Day 90 400 P = 0.27 P = 0.10 350 300 250 200 150 Patients Alive Patients 100 50 0 0 10 20 30 40 50 60 70 80 90 Days Since Drug Initiation Vasopressin Norepinephrine Russell JA, et al.
    [Show full text]
  • Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion and Pharmacokinetics
    TESI DOCTORAL HUMAN PHARMACOLOGY OF AYAHUASCA JORDI RIBA Barcelona, 2003 Director de la Tesi: DR. MANEL JOSEP BARBANOJ RODRÍGUEZ A la Núria, el Marc i l’Emma. No pasaremos en silencio una de las cosas que á nuestro modo de ver llamará la atención... toman un bejuco llamado Ayahuasca (bejuco de muerto ó almas) del cual hacen un lijero cocimiento...esta bebida es narcótica, como debe suponerse, i á pocos momentos empieza a producir los mas raros fenómenos...Yo, por mí, sé decir que cuando he tomado el Ayahuasca he sentido rodeos de cabeza, luego un viaje aéreo en el que recuerdo percibia las prespectivas mas deliciosas, grandes ciudades, elevadas torres, hermosos parques i otros objetos bellísimos; luego me figuraba abandonado en un bosque i acometido de algunas fieras, de las que me defendia; en seguida tenia sensación fuerte de sueño del cual recordaba con dolor i pesadez de cabeza, i algunas veces mal estar general. Manuel Villavicencio Geografía de la República del Ecuador (1858) Das, was den Indianer den “Aya-huasca-Trank” lieben macht, sind, abgesehen von den Traumgesichten, die auf sein persönliches Glück Bezug habenden Bilder, die sein inneres Auge während des narkotischen Zustandes schaut. Louis Lewin Phantastica (1927) Agraïments La present tesi doctoral constitueix la fase final d’una idea nascuda ara fa gairebé nou anys. El fet que aquest treball sobre la farmacologia humana de l’ayahuasca hagi estat una realitat es deu fonamentalment al suport constant del seu director, el Manel Barbanoj. Voldria expressar-li la meva gratitud pel seu recolzament entusiàstic d’aquest projecte, molt allunyat, per la natura del fàrmac objecte d’estudi, dels que fins al moment s’havien dut a terme a l’Àrea d’Investigació Farmacològica de l’Hospital de Sant Pau.
    [Show full text]
  • Nialamide; SOCIETIES and LECTURES CORRECTION
    414 BRITISH MEDICAL JOURNAL 15 MAY 1971 care, and administration of health services. A. Clements, P. A. Connell, Patricia A. Crawford, G. A. Cupper, M. R. Dean, L. L. Dom- "It is, in short, medicine applied to a group SOCIETIES AND LECTURES bey, D. P. De Bono, J. P. Delamere, Gil- than to an individual patient." The lean P. Duncan, D. B. Dunger, C. E. G. Farqu- rather Br Med J: first published as 10.1136/bmj.2.5758.414 on 15 May 1971. Downloaded from statement adds that it is hoped that the pro- For attending lectures marked * a fee is charged or harson, Pamela C. Fenney, Daphne C. Fielding, a ticket is required. Applications should be made I. R. Fletcher, M. S. Fletcher, Po-Kai Fok, G. J. visional Faculty will be in a position to re- Frost, R. M. Galbraith, Elizabeth A. S. Galvin, first to the institution concerned. D. J. Giraldi, Jenifer I. Glover, B. A. Greenway, ceive applications from those wishing to be- Mary Griffin, J. F. Hamlyn, M. H. Hampton, come founder members later in the year. Monday, 17 May G. P. Harris, P. B. Harvey, A. C. Hillyard, Gillian M. M. Hodge, N. Holmes, Sheilagh M. Further announcements will be made. ABERDEEN UNIVERSITY.-At Medical Buildings, Hope, C. C. Hugh, Joanna E. Ide, Alison Ironside, Foresterhill, 5.30 p.m., dentj centennial lecture Keatley E. James, W. J. Jarrett, Celia A. Jenkins, by Sir Robert Bradlaw: Pigmentation. J. R. Jenner, P. D. Jones, C. L. Kennedy, N. D. Monoamine-oxidase Inhibitors INSTITUTE OF DERMATOLOGY.-4.30 p.m., Mr.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0136742 A1 Mickle Et Al
    US 20110136742A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0136742 A1 Mickle et al. (43) Pub. Date: Jun. 9, 2011 (54) ANTIDEPRESSANT PRODRUGS A 6LX 3/5.375 (2006.01) A 6LX 3/553 (2006.01) (76) Inventors: Travis Mickle, Coralville, IA (US); A6II 3/42 (2006.01) Wendy Hirschelman Severs, A6II 3/44 (2006.01) Blacksburg, VA (US) A6II 3/42 (2006.01) A6II 3/405 (2006.01) (21) Appl. No.: 12/280,190 A63L/36 (2006.01) A63/4985 (2006.01) (22) PCT Fled: Feb. 22, 2007 A6II 3/4409 (2006.01) A6II 3/554 (2006.01) A6II 3/405 (2006.01) S371 (c)(1), A6IP 25/24 (2006.01) (2), (4) Date: Sep. 14, 2010 A6IP 25/22 (2006.01) Related U.S. Application Data A6IP 25/18 (2006.01) (52) U.S. Cl. ........ 514/17.6: 514/564: 514/321; 514/217; (60) Provisional application No. 60/776,216, filed on Feb. 514/237.8: 514/211.13: 514/378: 514/354; 24, 2006. 514/376; 514/.424; 514/239.2: 514/.466; 514/250; 514/423: 514/419 Publication Classification (57) ABSTRACT (51) Int. Cl. A6 IK 38/06 (2006.01) The invention provides antidepressant prodrugs comprising A6 IK 38/05 (2006.01) an antidepressant conjugated to one or more amino acids. The A 6LX 3L/95 (2006.01) invention also relates to pharmaceutical compositions com A6 IK 3L/4525 (2006.01) prising an antidepressant prodrug, and to methods of prepar A6 IK3I/55 (2006.01) ing and using the same.
    [Show full text]
  • Septic Shock Management Guided by Ultrasound: a Randomized Control Trial (SEPTICUS Trial)
    Septic Shock Management Guided by Ultrasound: A Randomized Control Trial (SEPTICUS Trial) RESEARCH PROTOCOL dr. Saptadi Yuliarto, Sp.A(K), MKes PEDIATRIC EMERGENCY AND INTENSIVE THERAPY SAIFUL ANWAR GENERAL HOSPITAL, MALANG MEDICAL FACULTY OF BRAWIJAYA UNIVERSITY DECEMBER 30, 2020 1 SUMMARY Research Title Septic Shock Management Guided by Ultrasound: A Randomized Control Trial (SEPTICUS Trial) Research Design A multicentre experimental study in pediatric patients with a diagnosis of septic shock. Research Objective To examine the differences in fluid resuscitation outcomes for septic shock patients with the USSM and mACCM protocols • Patient mortality rate • Differences in clinical parameters • Differences in macrocirculation hemodynamic parameters • Differences in microcirculation laboratory parameters Inclusion/Exclusion Criteria Inclusion: Pediatric patients (1 month - 18 years old), diagnosed with septic shock Exclusion: patients with congenital heart defects, already receiving fluid resuscitation or inotropic-vasoactive drugs prior to study recruitment, patients after cardiac surgery Research Setting A multicenter study conducted in all pediatric intensive care units (HCU / PICU), emergency department (IGD), and pediatric wards in participating hospitals in Indonesia. Sample Size Calculating the minimum sample size using the clinical trial formula for the mortality rate, obtained a sample size of 340 samples. Research Period The study was carried out in the period January 2021 to December 2022 Data Collection Process Pediatric patients who met the study inclusion criteria were randomly divided into 2 groups, namely the intervention group (USSM protocol) or the control group (mACCM protocol). Patients who respond well to resuscitation will have their outcome analyzed in the first hour (15-60 minutes). Patients with fluid refractory shock will have their output analyzed at 6 hours.
    [Show full text]
  • Vasoplegic Syndrome After Pediatric Cardiac Surgery
    Journal of Anesthesia & Critical Care: Open Access Review Article Open Access Vasoplegic syndrome after pediatric cardiac surgery Abstract Volume 12 Issue 3 - 2020 Vasoplegic syndrome (VS) is a form of vasodilatory shock that occurs in the early period in Pınar Yıldırım Özkan,1 Ahmet Akyol,1 pek patients who undergo cardiac surgery requiring cardiopulmonary bypass (CBP). Vasoplegic 2 1 1 syndrome, reported between 9 and 44%, is characterized by severe hypotension,severe Erus, AhuBaysal Çitil, Ayşe Duygu Kavas, 3 decrease in systemic vascular resistance, decreased arteriolar reactivity, need for increased Ahmet Ero lu İ 1 volume, and decreased response to norepinephrine, despite normal ardiac outflow. The University of Health Sciences, Ümraniye Training and Vasoplegia is associated with high mortality and morbidity, especially in pediatric patients. Research Hospital,ğ Clinic of Anesthesiology and Intensive Care, The pathophysiology of vasoplegic syndrome includes disruption of the arteriolar tone, Turkey 2Koc University, Medical Faculty, Clinic of Anesthesiology and which is regulated by endothelial function and neurohumoral system.Methylene blue is Intensive Care, Turkey safely used when administered at a dose below 2mg/kg while more prospective randomized 3KTU, Medical Faculty, Clinic of Anesthesiology and Intensive controlled trials are needed to determine the effective dose range. Care, Turkey Keywords: vasoplegic syndrome, pediatric, cardiac surgery, methylene blue, Correspondence: Assoc. Prof.Dr.Ahmet AKYOL, The cardiyopulmoner bypass, prostaglandin infusion, pleth variability index, cross clamp University of Health Sciences, Ümraniye Training and Research Hospital, Clinic of Anesthesiology and Intensive Care, ElmalikentMah. AdemYavuz Cad. No: 1. (34764) Ümraniye, stanbul, Turkey, Tel +90 533 6331369, Email İ Received: April 29, 2020 | Published: May 21, 2020 Introduction min), SpO2 was 85%, BP 69/37 mmHg, and pulse 168/min at room temperature.
    [Show full text]
  • Vasopressin, Norepinephrine, and Vasodilatory Shock After Cardiac Surgery Another “VASST” Difference?
    Vasopressin, Norepinephrine, and Vasodilatory Shock after Cardiac Surgery Another “VASST” Difference? James A. Russell, A.B., M.D. AJJAR et al.1 designed, Strengths of VANCS include H conducted, and now report the blinded randomized treat- in this issue an elegant random- ment, careful follow-up, calcula- ized double-blind controlled trial tion of the composite outcome, of vasopressin (0.01 to 0.06 U/ achieving adequate and planned Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/126/1/9/374893/20170100_0-00010.pdf by guest on 01 October 2021 min) versus norepinephrine (10 to sample size, and evaluation of 60 μg/min) post cardiac surgery vasopressin pharmacokinetics. with vasodilatory shock (Vaso- Nearly 20 yr ago, Landry et al.2–6 pressin versus Norepinephrine in discovered relative vasopressin defi- Patients with Vasoplegic Shock ciency and benefits of prophylactic After Cardiac Surgery [VANCS] (i.e., pre cardiopulmonary bypass) trial). Open-label norepinephrine and postoperative low-dose vaso- was added if there was an inad- pressin infusion in patients with equate response to blinded study vasodilatory shock after cardiac drug. Vasodilatory shock was surgery. Previous trials of vasopres- defined by hypotension requiring sin versus norepinephrine in cardiac vasopressors and a cardiac index surgery were small and underpow- greater than 2.2 l · min · m-2. The “[The use of] …vasopressin ered for mortality assessment.2–6 primary endpoint was a compos- Vasopressin stimulates arginine ite: “mortality or severe complica- infusion for treatment of vasopressin receptor 1a, arginine tions.” Patents with vasodilatory vasodilatory shock after vasopressin receptor 1b, V2, oxy- shock within 48 h post cardiopul- tocin, and purinergic receptors monary bypass weaning were eli- cardiac surgery may causing vasoconstriction (V1a), gible.
    [Show full text]